Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation Analysis in the Diagnosis of Lower-Risk Myelodysplastic Syndrome

Incorporating the CD36 CV into flow cytometric evaluation enhances diagnostic specificity for lower-risk MDS without requiring additional antibody panels. This locally validated marker may improve diagnostic accuracy when combined with myelomonocytic immunophenotyping. Standardization across institutions remains necessary for broader applicability.